TR199900399T2 - Matris metaloproteaz inhibitörleri olarak fosfinik asit amidleri. - Google Patents
Matris metaloproteaz inhibitörleri olarak fosfinik asit amidleri.Info
- Publication number
- TR199900399T2 TR199900399T2 TR1999/00399T TR9900399T TR199900399T2 TR 199900399 T2 TR199900399 T2 TR 199900399T2 TR 1999/00399 T TR1999/00399 T TR 1999/00399T TR 9900399 T TR9900399 T TR 9900399T TR 199900399 T2 TR199900399 T2 TR 199900399T2
- Authority
- TR
- Turkey
- Prior art keywords
- compounds
- matrix metalloprotease
- acid amides
- phosphinic acid
- metalloprotease inhibitors
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000005741 Metalloproteases Human genes 0.000 abstract 2
- 108010006035 Metalloproteases Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Bulus, istemlerde tarif edildigi haliyle (1) formülü bilesiklerini, ya da bu bilesiklerin bir optik izomeri, diastereomeri ya da enantiomeri, ya da farmasötik açidan kabul edilebilir bir tuzunu ya da biyo-hidrolize-edilebilir amidi, esteri ya da imidini temin etmektedir, bu maddeler matris metaloproteazlarin inhibitörleri olarak yararlidir, bu formüldeki, R1, R2, R3 ve R4 istemlerde anlatildigi gibidir. Ayni zamanda, matris metaloproteaz etkinligi ile vasiflanan hastaliklar, bozukluklar ve durumlarin, bu bilesikler ya da bu bilesikleri ihtiva eden farmasötik bilesim kullanilarak tedavisi edilmesi için yöntemler ve farmasötik bilesimler de anlatilmistir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2476596P | 1996-08-28 | 1996-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR199900399T2 true TR199900399T2 (tr) | 1999-06-21 |
Family
ID=21822291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR1999/00399T TR199900399T2 (tr) | 1996-08-28 | 1997-08-22 | Matris metaloproteaz inhibitörleri olarak fosfinik asit amidleri. |
Country Status (27)
Country | Link |
---|---|
US (1) | US5830915A (tr) |
EP (1) | EP0925303B1 (tr) |
JP (1) | JP3539736B2 (tr) |
KR (1) | KR20000035925A (tr) |
CN (1) | CN1228780A (tr) |
AR (1) | AR009357A1 (tr) |
AT (1) | ATE226590T1 (tr) |
AU (1) | AU732653B2 (tr) |
BR (1) | BR9713182A (tr) |
CA (1) | CA2264254C (tr) |
CO (1) | CO4900033A1 (tr) |
CZ (1) | CZ63699A3 (tr) |
DE (1) | DE69716619T2 (tr) |
DK (1) | DK0925303T3 (tr) |
HU (1) | HUP9903916A3 (tr) |
ID (1) | ID18145A (tr) |
IL (1) | IL128668A (tr) |
NO (1) | NO990857L (tr) |
NZ (1) | NZ334258A (tr) |
PE (1) | PE107698A1 (tr) |
PL (1) | PL331854A1 (tr) |
RU (1) | RU2170232C2 (tr) |
SK (1) | SK25499A3 (tr) |
TR (1) | TR199900399T2 (tr) |
TW (1) | TW518338B (tr) |
WO (1) | WO1998008853A1 (tr) |
ZA (1) | ZA977700B (tr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206874A1 (en) * | 1996-11-21 | 2003-11-06 | The Proctor & Gamble Company | Promoting whole body health |
BR9810841A (pt) | 1997-07-31 | 2001-07-10 | Procter & Gamble | Inibidores de metaloprotease alicìclicos |
US6846478B1 (en) | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
DE19850072A1 (de) * | 1998-10-30 | 2000-05-04 | Bayer Ag | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
EP1144369B1 (en) * | 1999-01-27 | 2004-07-21 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
CN1178915C (zh) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途 |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
AR035313A1 (es) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
EP1165501A1 (en) | 1999-03-03 | 2002-01-02 | The Procter & Gamble Company | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
US6312474B1 (en) * | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
EP1294367B1 (en) * | 2000-06-30 | 2008-07-16 | The Procter & Gamble Company | Oral compositions comprising host-response modulating agent |
US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
PT1294383E (pt) * | 2000-06-30 | 2008-10-08 | Procter & Gamble | Composições orais compreendendo agentes antimicrobianos |
MXPA03000277A (es) * | 2000-07-18 | 2004-04-05 | Leo Pharma As | Inhibidores de metaloproteinasa de matriz. |
FR2814950B1 (fr) * | 2000-10-05 | 2003-08-08 | Oreal | Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement |
US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
US6693099B2 (en) * | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
AU2003205544A1 (en) | 2002-01-18 | 2003-07-30 | Leo Pharma A/S | Mmp inhibitors |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US7144588B2 (en) | 2003-01-17 | 2006-12-05 | Synovis Life Technologies, Inc. | Method of preventing surgical adhesions |
EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
US8198445B2 (en) * | 2007-03-09 | 2012-06-12 | National University Corporation Nagoya University | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol |
TW201141536A (en) | 2009-12-21 | 2011-12-01 | Colgate Palmolive Co | Oral care compositions and methods |
EP2726073A1 (en) * | 2011-06-29 | 2014-05-07 | Janssen Pharmaceutica, N.V. | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases |
RU2488587C1 (ru) * | 2012-05-23 | 2013-07-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский национальный исследовательский технологический университет" | Анилид гидроксиметиланилинометилфосфиновой кислоты (амидофос) в качестве биостимулятора активного ила в процессе очистки сточных вод и способ его получения |
HUE061437T2 (hu) | 2015-10-23 | 2023-06-28 | Navitor Pharm Inc | A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai |
US20190008828A1 (en) | 2015-12-28 | 2019-01-10 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
CN107709288A (zh) * | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
IL307232A (en) * | 2016-04-29 | 2023-11-01 | Ophirex Inc | PLA2 and HMG-COA suppressors for the treatment of pathological diseases that cause hemolysis, brain edema and acute kidney injury |
CN106905183B (zh) * | 2017-02-24 | 2018-07-31 | 三峡大学 | 一类含氨基的ɑ-酰氧基羰基酰胺类衍生物,制备方法及其应用 |
WO2018200625A1 (en) * | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
CA3117336A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 |
US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601368D0 (en) * | 1986-01-21 | 1986-02-26 | Ici America Inc | Hydroxamic acids |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
DE4011172A1 (de) * | 1990-04-06 | 1991-10-10 | Degussa | Verbindungen zur bekaempfung von pflanzenkrankheiten |
US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) * | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
IL98681A (en) * | 1991-06-30 | 1997-06-10 | Yeda Rehovot And Dev Company L | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives |
DE4127842A1 (de) * | 1991-08-22 | 1993-02-25 | Rhone Poulenc Rorer Gmbh | 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate |
JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
US5525629A (en) * | 1992-04-07 | 1996-06-11 | British Bio-Technology Limited | Inhibition of cytokine production |
AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
DK0766665T3 (da) * | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
-
1997
- 1997-08-22 NZ NZ334258A patent/NZ334258A/xx unknown
- 1997-08-22 AU AU41531/97A patent/AU732653B2/en not_active Ceased
- 1997-08-22 BR BR9713182-2A patent/BR9713182A/pt unknown
- 1997-08-22 EP EP97939444A patent/EP0925303B1/en not_active Expired - Lifetime
- 1997-08-22 WO PCT/US1997/014556 patent/WO1998008853A1/en not_active Application Discontinuation
- 1997-08-22 DE DE69716619T patent/DE69716619T2/de not_active Expired - Fee Related
- 1997-08-22 CZ CZ99636A patent/CZ63699A3/cs unknown
- 1997-08-22 TR TR1999/00399T patent/TR199900399T2/tr unknown
- 1997-08-22 IL IL12866897A patent/IL128668A/en not_active IP Right Cessation
- 1997-08-22 KR KR1019997001661A patent/KR20000035925A/ko active IP Right Grant
- 1997-08-22 SK SK254-99A patent/SK25499A3/sk unknown
- 1997-08-22 CA CA002264254A patent/CA2264254C/en not_active Expired - Fee Related
- 1997-08-22 JP JP51171698A patent/JP3539736B2/ja not_active Expired - Fee Related
- 1997-08-22 AT AT97939444T patent/ATE226590T1/de not_active IP Right Cessation
- 1997-08-22 RU RU99106245/04A patent/RU2170232C2/ru active
- 1997-08-22 HU HU9903916A patent/HUP9903916A3/hu unknown
- 1997-08-22 DK DK97939444T patent/DK0925303T3/da active
- 1997-08-22 CN CN97197546A patent/CN1228780A/zh active Pending
- 1997-08-22 PL PL97331854A patent/PL331854A1/xx unknown
- 1997-08-26 US US08/918,950 patent/US5830915A/en not_active Expired - Fee Related
- 1997-08-27 ZA ZA9707700A patent/ZA977700B/xx unknown
- 1997-08-27 CO CO97049512A patent/CO4900033A1/es unknown
- 1997-08-27 AR ARP970103898A patent/AR009357A1/es unknown
- 1997-08-28 ID IDP972999A patent/ID18145A/id unknown
- 1997-08-28 PE PE1997000765A patent/PE107698A1/es not_active Application Discontinuation
-
1998
- 1998-02-03 TW TW087101222A patent/TW518338B/zh active
-
1999
- 1999-02-23 NO NO990857A patent/NO990857L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2000515167A (ja) | 2000-11-14 |
KR20000035925A (ko) | 2000-06-26 |
CA2264254C (en) | 2003-03-11 |
EP0925303A1 (en) | 1999-06-30 |
NZ334258A (en) | 2000-11-24 |
AR009357A1 (es) | 2000-04-12 |
ID18145A (id) | 1998-03-05 |
AU732653B2 (en) | 2001-04-26 |
TW518338B (en) | 2003-01-21 |
AU4153197A (en) | 1998-03-19 |
RU2170232C2 (ru) | 2001-07-10 |
CZ63699A3 (cs) | 1999-07-14 |
PE107698A1 (es) | 1999-02-11 |
WO1998008853A1 (en) | 1998-03-05 |
US5830915A (en) | 1998-11-03 |
DE69716619D1 (en) | 2002-11-28 |
HUP9903916A2 (hu) | 2001-05-28 |
BR9713182A (pt) | 1999-11-03 |
CA2264254A1 (en) | 1998-03-05 |
CO4900033A1 (es) | 2000-03-27 |
SK25499A3 (en) | 2000-03-13 |
PL331854A1 (en) | 1999-08-16 |
DK0925303T3 (da) | 2003-02-24 |
IL128668A0 (en) | 2000-01-31 |
NO990857L (no) | 1999-04-28 |
IL128668A (en) | 2002-02-10 |
ZA977700B (en) | 1998-02-23 |
CN1228780A (zh) | 1999-09-15 |
ATE226590T1 (de) | 2002-11-15 |
DE69716619T2 (de) | 2003-06-26 |
HUP9903916A3 (en) | 2001-06-28 |
JP3539736B2 (ja) | 2004-07-07 |
EP0925303B1 (en) | 2002-10-23 |
NO990857D0 (no) | 1999-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199900399T2 (tr) | Matris metaloproteaz inhibitörleri olarak fosfinik asit amidleri. | |
TR199900428T2 (tr) | 1,4-Heterosiklik metaloproteaz inhibitörleri. | |
TR199900383T2 (tr) | 1,3-Diheterosiklik metaloproteaz inhibitörleri. | |
TR199900382T2 (tr) | Heterosiklik metaloproteaz inhibitörleri. | |
TR199900429T2 (tr) | Spirosiklik metaloproteaz inhibitörleri. | |
WO1999006340A3 (en) | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors | |
ATE427300T1 (de) | Heterocyclisch substituierte amide als calpainhemmer | |
MY117896A (en) | Quinazoline derivatives | |
TR199900431T2 (tr) | Ikame edilmis siklik amin metaloproteaz inhibitörleri | |
AU7527901A (en) | Caspase inhibitors and uses thereof | |
EA199800184A1 (ru) | Соединение бензимидазола | |
WO2001090070A3 (en) | Caspase inhibitors and uses thereof | |
FI961809A0 (fi) | Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit | |
ATE128143T1 (de) | 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung. | |
TR200002971T2 (tr) | İkameli pirolidin hidroksamat metaloproteaz inhibitörleri | |
ATE289590T1 (de) | Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren | |
WO2000051993A3 (en) | Dihetero-substituted metalloprotease inhibitors | |
TR199900401T2 (tr) | Bidentat metaloproteaz inhibitörleri. | |
TR200102523T2 (tr) | Alkenil ve alkinil içeren metaloproteaz inhibitörleri | |
BR0109328A (pt) | Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica | |
WO2001070720A3 (en) | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors | |
PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
HUP0303636A2 (hu) | Dihidronaftalin-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
TR200000720T2 (tr) | Kuinolin türevlerinin sentezi için metod. | |
WO2001070693A3 (en) | Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |